AstraZeneca stock price forecast: GBX13,618.47 resistance as AZN trades flat

Traders Union
All News
Financial News
AstraZeneca gains 0.68% after FDA news

Highlights

AstraZeneca received FDA priority review for expanding Ultomiris in IgA nephropathy, enabling quicker access to a larger patient base.
Strong Q1 earnings reaffirm AstraZeneca's operational momentum and continued resilience in its financial performance.
AZN/GBX faces persistent bearish momentum with high probability of range-bound or downward price action between GBX13,077.53 and GBX13,618.47.

Sales optimism rises as FDA accelerates Ultomiris review

AstraZeneca has secured FDA acceptance for its regulatory filing to expand the use of Ultomiris (ravulizumab) in treating immunoglobulin A nephropathy (IgAN), with the application granted priority review. This accelerated regulatory process increases the likelihood of reaching a larger patient population sooner, fueling expectations of higher future sales for Ultomiris and supporting fresh buying interest in the stock. The company also reported strong first-quarter results, which reinforce the story of operational momentum and earnings resilience.

Momentum stays bearish as technical boundaries cap gains

AZN is trading above its MA-20 at GBX13,310.63 but remains below the MA-50 at GBX13,464.83 on the hourly chart and the MA-200 at GBX13,593.56 on the daily. The Ichimoku Kijun level at GBX12,634.00 provides immediate support. Momentum indicators show MACD and ADX in strong sell configuration, while the RSI stands at 42.1 (sell). The Stoch RSI and BBP both signal overbought conditions intraday, with CCI and Awesome Oscillator classified as neutral. Despite intraday overbought readings, the broader momentum picture remains negative with sellers dominating.

Consolidation favored as breakout risks point to volatility

Over the next several trading days, AZN is expected to fluctuate within a volatility band of GBX13,077.53 to GBX13,618.47. An upward breakout above GBX13,618.47 could prompt a test of additional short-term resistance. Conversely, a drop below GBX13,077.53 would likely trigger increased selling activity and open the way for deeper support tests. The baseline scenario remains price consolidation inside this forecast corridor.

Viktoras Karapetjanc, expert at Traders Union, sees AstraZeneca’s FDA priority review for Ultomiris as strong regulatory momentum. He believes recent earnings resilience and operational strength add to institutional confidence. Short-term sentiment is constructive, even if broader technicals remain mixed. He expects demand to be supported on any dips near key levels in the GBX13,077.53–GBX13,618.47 corridor. "With regulatory momentum and strong results, I view AstraZeneca as a buy on consolidation pullbacks."

Earlier, analysts noted that AstraZeneca shares remained under persistent selling pressure despite positive clinical and regulatory developments, reinforcing a broadly bearish technical outlook. While the latest regulatory progress and improved earnings have fueled a short-term rebound, traders should monitor whether this momentum can translate into a sustained shift or merely results in further price consolidation within the established volatility range.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.